ProMIS Neurosciences Earnings Call Transcripts
Fiscal Year 2026
-
Enrollment in a robust phase 1b Alzheimer's trial is complete, with interim and final data expected this year. The proprietary EpiSelect platform enables highly selective targeting of toxic oligomers, aiming for improved efficacy and safety. Strong financing and high retention support a pivotal year.
Fiscal Year 2025
-
The conference highlighted progress in a phase I-B Alzheimer's trial, with enrollment on track and interim safety and biomarker data expected next year. The lead antibody targets toxic oligomers, aiming for superior safety and efficacy, and may advance rapidly to phase III if results are positive.
-
A novel antibody targeting toxic amyloid beta oligomers in Alzheimer’s is in a robust phase 1b trial, with interim biomarker data expected mid-next year and final results by year-end. The approach aims to improve efficacy and safety by avoiding plaque and ARIA, drawing strong industry interest.
-
A novel antibody therapy targeting toxic amyloid beta oligomers in Alzheimer's is advancing through a robust Phase Ib trial, showing strong safety and no ARIA cases so far. Interim results are expected in Q2 next year, with a potential for rapid progression to Phase III.
-
Alzheimer's disease remains a major unmet need due to modest efficacy and significant side effects of current therapies, especially ARIA. A novel antibody, PMN-310, selectively targets toxic amyloid oligomers, aiming to improve efficacy and safety, with phase 1B interim results expected next year.
-
PMN 310’s phase 1b Alzheimer’s trial is underway, targeting toxic oligomers to improve safety and efficacy over current therapies. Interim results are expected in H1 2026, with strong physician and strategic partner interest driven by a differentiated approach and robust preclinical data.